Amwell (AMWL) Q1 2026 earnings review
Surviving, but Shrinking: Profitability Accelerates as the Top Line Evaporates
Amwell's Q1 results reveal a stark contrast between strong operational discipline and a deteriorating top line. Revenue decelerated further to $54.9M (down 18% YoY), driven by the ongoing digestion of the Defense Health Agency (DHA) contract step-down and divestitures. However, the company's aggressive cost-cutting measures are working: Net Loss improved significantly to $10.3M, and Adjusted EBITDA loss shrank to just $3.1M. While the promised Q4 cash flow breakeven looks highly credible, the underlying revenue mix shifted unfavorably this quarter, calling into question the narrative of becoming a high-margin software utility.
🐂 Bull Case
An Adjusted EBITDA loss of just $3.1M marks an incredible turnaround from a year ago (-$12.2M). The company is on a very credible path to generating positive operating cash flow by Q4 2026.
Cash burn has been arrested. With $180M in cash and equivalents remaining and the burn rate dramatically reduced, existential liquidity risks have been largely removed.
🐻 Bear Case
Revenue is not just shrinking; it's still decelerating. Q2 guidance of $50M at the midpoint implies a continuation of the negative trajectory, capping upside potential.
The company faces a binary event risk with the Defense Health Agency (DHA) contract renewal slated for Summer 2026. Management previously admitted this is the primary engine of their software revenue.
⚖️ Verdict: ⚪
Neutral. Management deserves credit for executing a painful but necessary cost rationalization that saved the balance sheet. However, you can't cut your way to growth, and the deteriorating quality of the revenue mix makes this a 'show me' story.
Key Themes
Data Contradicts Software Pivot Narrative
Management has repeatedly claimed they are accepting lower top-line growth to transition into a high-quality, sticky subscription software business. The Q1 data explicitly contradicts this narrative: Subscription revenue reversed its growth and dropped to $24.9M (down 22.6% YoY), while lower-margin Amwell Medical Group (AMG) visit revenue surprisingly accelerated to $28.9M (up 8.6% YoY). This adverse mix shift directly explains why gross margin compressed to 51% (vs 53% in 25Q1).
Aggressive Cost Controls Driving Profitability
The relentless operational diet continues to pay massive dividends. Operating expenses are drastically lower across the board. The drop in Net Loss to $10.3M from $25.2M just one quarter ago proves that management's commitment to right-sizing operations is accelerating, paving the way for cash flow generation.
DHA Contract Risk Looms Large
The summer 2026 renewal of the Defense Health Agency (DHA) contract remains the single largest overhang on the stock. After the DoD previously stripped out behavioral health and automated care programs during the 2025 renewal, investors remain rightfully anxious about the upcoming negotiations. Losing this would be, in management's own prior words, an 'existential threat'.
Positioning as the AI Integration Utility
Amwell's core go-to-market strategy has shifted from being a telehealth provider to serving as the foundational IT infrastructure. By allowing clients to seamlessly integrate third-party AI innovations (like GLP-1 or MSK management programs) under a single white-labeled roof, Amwell solves the 'vendor sprawl' problem, making its core platform deeply embedded within payer workflows.
Macro Tailwinds: Payer Margin Compression
Rising healthcare costs, particularly from high-cost drugs like GLP-1s, and broad payer margin compression are acting as macro drivers. Payers are forced to consolidate digital point solutions to drive efficiencies, which aligns perfectly with Amwell's positioning as an enterprise integrator that replaces fragmented tools.
Visit Volumes Structurally Depressed
Total platform visits landed at 1.1 million for the quarter. While stable sequentially against Q4 2025, this is a distinct deceleration from the 1.3 million logged in Q1 2025. The platform is seeing less utilization, capping the potential for organic, volume-driven growth.
Other KPIs
Stable. Only slightly down from $182.3 million at the end of 2025. This indicates that operating cash burn has been largely arrested. With capital expenditures minimal ($5,000 for the quarter) and capitalized software costs well managed, the runway is more than sufficient to reach the Q4 breakeven target.
Decelerating. This metric came in at 51%, down from 53% a year ago and below the 56.1% peak seen in 25Q2. The margin erosion is primarily driven by the surprising reversal in revenue mix, where lower-margin services (AMG) outpaced high-margin software subscriptions.
Guidance
Decelerating. At the $50M midpoint, this implies a sequential decline from Q1's $54.9M and represents a sharp contraction against the prior-year period. It reflects continued structural shrinking before hitting an anticipated floor.
Stable. The midpoint of ($3.0) million implies the company will maintain the massive profitability improvements achieved in Q1, proving the cost cuts are structural rather than one-time events.
Reiterated. Maintains the deeply suppressed revenue base established after shedding non-core assets and dealing with the DHA scope reduction. Achieving this requires approximately $50M per quarter, meaning the back half of the year must remain perfectly stable with no further decay.
Reiterated. The target implies a significant year-over-year improvement. Given the Q1 result of ($3.1)M, the company is tracking perfectly to hit the midpoint, requiring no heroic operational leaps in the back half of the year.
Key Questions
Software Revenue Drop
Subscription revenue dropped to $24.9M while AMG visits grew to $28.9M. This completely contradicts the narrative of pivoting toward a higher-margin software business. What specifically caused this adverse mix shift in Q1, and when will software begin growing again?
DHA Renewal Update
We are fast approaching the Summer 2026 renewal window for the DHA contract. Has there been any indication from the DoD regarding their intent to renew, and are there active discussions about re-adding the behavioral health modules that were previously cut?
Revenue Floor Timing
Guidance implies total revenue will hover around $50M per quarter for the rest of the year. Do you view $195M-$205M as the absolute revenue floor, or are there remaining legacy contracts slated to roll off in 2027?